PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33936221-5	2021	In the current study, we assessed the cytotoxic effects of idarubicin-ZHER2 affibody conjugate on the positive-HER2 cancer cell lines.	Idarubicin	59-69	erb-b2 receptor tyrosine kinase 2	Homo sapiens	71-75	
33936221-10	2021	Conclusion: The ZHER2-affibody conjugate of idarubicin has a more specific cytotoxic effect compared with idarubicin alone against HER2-overexpressing ovarian cancerous cells.	Idarubicin	44-54	erb-b2 receptor tyrosine kinase 2	Homo sapiens	17-21	
33936221-10	2021	Conclusion: The ZHER2-affibody conjugate of idarubicin has a more specific cytotoxic effect compared with idarubicin alone against HER2-overexpressing ovarian cancerous cells.	Idarubicin	106-116	erb-b2 receptor tyrosine kinase 2	Homo sapiens	17-21	
33936221-11	2021	It appears the ZHER2-affibody conjugate of idarubicin has great potential to be implicated as an innovative anti-cancer agent in future clinical trials in patients with HER2-overexpressing ovarian cancer.	Idarubicin	43-53	erb-b2 receptor tyrosine kinase 2	Homo sapiens	16-20